This Biotech Wins a Big FDA Approval. Why Wall Street Is Shrugging.

Lilly Builds Neuroscience into a New Long-Term Growth Driver

Canada’s Drug Agency Issues Final Positive Recommendation Supporting Public Reimbursement of LEQEMBI® (lecanemab) for Early Alzheimer’s Disease

LEQEMBI® (lecanemab) Subcutaneous Formulation as an Initiation Treatment for Early Alzheimer’s Disease Approved in China

Register Now: Limited Seating Remains for HMG Strategy’s Sept. 10 Boston C-Level Technology Leadership Summit

Why Is Biogen (BIIB) Up 6.5% Since Last Earnings Report?

Biogen’s (BIIB) Immunology Bet Meets A Pricier Balance Sheet

Biogen (BIIB) Stock Could Be 48% Below Fair Value On New Dravet Data

Biogen (BIIB) Brings At Home Weekly Alzheimer’s Injection To U.S. Patients

Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)